Literature DB >> 7747720

Secondary hyperparathyroidism in renal failure: the trade-off hypothesis revisited.

F Llach1.   

Abstract

Our understanding of the mechanism responsible for secondary hyperparathyroidism (HPTH) has advanced significantly since the "trade-off" hypothesis was formulated. It appears that in early renal failure a deficit of calcitriol synthesis is an important factor. However, additional factors, such as a defect of the vitamin D receptor or the newly cloned calcium sensor receptor (BoPCaR1), may be present in the parathyroid cells. As renal failure progresses, the lack of calcitriol becomes more pronounced, inducing HPTH. With advanced chronic renal failure, hyperphosphatemia is an additional important factor in worsening HPTH. In addition, resistance of the parathyroids to calcitriol due to a reduced density of calcitriol receptors also may contribute to HPTH. Finally, uremia per se not only may cause a receptor abnormality in the parathyroid but at the level of the bone it may aggravate the impaired calcemic response to PTH. In conclusion, after reviewing the "trade-off" hypothesis, although some of the original concepts may have been simplistic, most of the factors postulated 30 years ago are still operative in the pathogenesis of secondary HPTH in renal failure.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747720     DOI: 10.1016/0272-6386(95)90541-3

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  17 in total

1.  Initial parathyroid surgery in 606 patients with renal hyperparathyroidism.

Authors:  Ralph Schneider; Emily P Slater; Elias Karakas; Detlef K Bartsch; Katja Schlosser
Journal:  World J Surg       Date:  2012-02       Impact factor: 3.352

Review 2.  Bone Disease in CKD in Children.

Authors:  Fernando Santos; Lucas Díaz-Anadón; Flor A Ordóñez; Dieter Haffner
Journal:  Calcif Tissue Int       Date:  2021-01-16       Impact factor: 4.333

Review 3.  Diseases of the parathyroid gland in chronic kidney disease.

Authors:  Hirotaka Komaba; Takatoshi Kakuta; Masafumi Fukagawa
Journal:  Clin Exp Nephrol       Date:  2011-08-06       Impact factor: 2.801

Review 4.  Chronic kidney disease and its complications.

Authors:  Robert Thomas; Abbas Kanso; John R Sedor
Journal:  Prim Care       Date:  2008-06       Impact factor: 2.907

5.  Elevated serum parathyroid hormone is a cardiovascular risk factor in moderate chronic kidney disease.

Authors:  Anton Lishmanov; Smrita Dorairajan; Youngju Pak; Kunal Chaudhary; Anand Chockalingam
Journal:  Int Urol Nephrol       Date:  2011-02-15       Impact factor: 2.370

6.  Ubiquitination-deubiquitination balance dictates ligand-stimulated PTHR sorting.

Authors:  Verónica Alonso; Clara E Magyar; Bin Wang; Alessandro Bisello; Peter A Friedman
Journal:  J Bone Miner Res       Date:  2011-12       Impact factor: 6.741

7.  Increase in bone mineral density after successful parathyroidectomy for tertiary hyperparathyroidism after renal transplantation.

Authors:  Stéphane Collaud; Tania Staub-Zähner; Andrea Trombetti; Thomas Clerici; Nicola Marangon; Isabelle Binet; Patrick O Myers; René Rizzoli; Pierre-Yves Martin; John H Robert; Frederic Triponez
Journal:  World J Surg       Date:  2008-08       Impact factor: 3.352

8.  Eight parathyroid glands incidentally discovered during a surgical intervention for secondary hyperparathyroidism: an unusual clinical finding.

Authors:  G Amato; E Lalli; G Mazziotti; G De Felice; M Rotondi; G Vitolo; A Saggese; A Livrea; A Bellastella; C Carella
Journal:  J Endocrinol Invest       Date:  2002-10       Impact factor: 4.256

Review 9.  Safety of new phosphate binders for chronic renal failure.

Authors:  Mahmoud Loghman-Adham
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

10.  Endoscopic total parathyroidectomy and partial parathyroid tissue autotransplantation for patients with secondary hyperparathyroidism: a new surgical approach.

Authors:  Yueming Sun; Huihua Cai; Jianfeng Bai; Hanlin Zhao; Yi Miao
Journal:  World J Surg       Date:  2009-08       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.